SUMMARY
Last month, the Drug Enforcement Administration moved to reschedule medical cannabis from Schedule I to Schedule III, setting the stage for a significant shift in the industry’s economic framework. The most consequential change would be the removal of Internal Revenue Code Section 280E, which has long forced cannabis operators to pay taxes on gross profit rather than pre-tax income. The key question for both operators and investors is how this regulatory shift will ultimately flow through to financial results—and, by extension, valuations.
In its final rule, the DOJ signaled that the Treasury Department and IRS should consider providing retrospective relief from Section 280E for prior tax years in which companies operated legally under state medical marijuana programs but were nevertheless subject to punitive 280E taxation. The Treasury Department is expected to address this issue in forthcoming guidance.
The elimination of Section 280E should serve as a meaningful catalyst for increased M&A activity across the cannabis sector, as improved after-tax cash flows, reduced tax uncertainty, and enhanced access to capital markets are likely to support higher transaction volumes and more aggressive consolidation strategies.